Department of Cellular and Molecular Medicine, Chosun University, Gwangju 61452, Republic of Korea.
Department of Chemistry, Chonnam National University, Gwangju 61186, Republic of Korea.
Biochim Biophys Acta Biomembr. 2019 Jan;1861(1):256-267. doi: 10.1016/j.bbamem.2018.06.016. Epub 2018 Jun 28.
CXCL14 is a CXC chemokine family that exhibits antimicrobial activity and contains an amphipathic cationic α-helical region in the C-terminus, a characteristic structure of antimicrobial peptides (AMPs). In this study, we designed three analogs of CXCL14 (named CXCL14-C17) corresponding to the C-terminal α-helix of CXCL14, which displayed potential antimicrobial activity against a wide variety of gram-negative and gram-positive bacteria with minimum inhibitory concentrations of 4-16 μM without mammalian cell toxicity. Furthermore, two CXCL14-C17 analogs (CXCL14-C17-a1 and CXCL14-C17-a3) with improved cell selectivity were engineered by introducing Lys, Arg, or Trp in CXCL14-C17. Additionally, CXCL14-C17 analogs showed much greater synergistic effect (FICI: 0.3125-0.375) with chloramphenicol and ciprofloxacin against multidrug-resistant Pseudomonas aeruginosa (MDRPA) than LL-37 did (FICI: 0.75-1.125). CXCL14-C17 analogs were more active against antibiotic-resistant bacteria including methicillin-resistant Staphylococcus aureus (MRSA), MDRPA, and vancomycin-resistant Enterococcus faecium (VREF) than LL-37 and melittin. In particular, CXCL14-C17-a2 and CXCL14-C17-a3 completely inhibited the biofilm formation at sub-MIC and all of the peptides were able to eliminate pre-formed biofilm as well. Membrane depolarization, flow cytometry, sytox green uptake, ONPG hydrolysis and confocal microscopy revealed the possible target of the native peptide (CXCL14-C17) to likely be intracellular, and the amphipathic designed analogs targeted the bacterial membrane. CXCL14-C17 also showed DNA binding characteristic activity similar to buforin-2. Interestingly, CXCL14-C17-a2 and CXCL14-C17-a3 effectively inhibited the production and expression of nitric oxide (NO), tumor necrosis factor (TNF)-α, interleukin (IL)-6, and monocyte chemoattractant protein (MCP)-1 from lipopolysaccharide (LPS)-stimulated RAW264.7 cells, suggesting that these peptides could be promising anti-inflammatory and antimicrobial agents.
CXCL14 是 CXC 趋化因子家族的一员,具有抗微生物活性,其 C 末端含有一个两亲性阳离子α-螺旋区,这是抗菌肽 (AMPs) 的特征结构。在这项研究中,我们设计了三个 CXCL14 的类似物(命名为 CXCL14-C17),对应于 CXCL14 的 C 末端α-螺旋,它们对多种革兰氏阴性和革兰氏阳性细菌表现出潜在的抗菌活性,最小抑菌浓度为 4-16 μM,对哺乳动物细胞没有毒性。此外,通过在 CXCL14-C17 中引入 Lys、Arg 或 Trp,设计了两种具有更高细胞选择性的 CXCL14-C17 类似物 (CXCL14-C17-a1 和 CXCL14-C17-a3)。此外,与 LL-37 相比(FICI:0.75-1.125),CXCL14-C17 类似物与氯霉素和环丙沙星对多药耐药铜绿假单胞菌 (MDRPA) 的协同作用更大(FICI:0.3125-0.375)。与 LL-37 和蜂毒素相比,CXCL14-C17 类似物对包括耐甲氧西林金黄色葡萄球菌 (MRSA)、MDRPA 和万古霉素耐药粪肠球菌 (VREF) 在内的抗生素耐药菌更具活性。特别是,CXCL14-C17-a2 和 CXCL14-C17-a3 在亚 MIC 下完全抑制生物膜的形成,并且所有肽都能够消除预先形成的生物膜。膜去极化、流式细胞术、SYTOX 绿色摄取、ONPG 水解和共聚焦显微镜显示,天然肽(CXCL14-C17)的可能靶标可能是细胞内的,而两亲性设计的类似物则靶向细菌膜。CXCL14-C17 还表现出与布福菌素-2 相似的 DNA 结合特征活性。有趣的是,CXCL14-C17-a2 和 CXCL14-C17-a3 有效抑制脂多糖 (LPS) 刺激的 RAW264.7 细胞中一氧化氮 (NO)、肿瘤坏死因子 (TNF)-α、白细胞介素 (IL)-6 和单核细胞趋化蛋白 (MCP)-1 的产生和表达,表明这些肽可能是有前途的抗炎和抗菌剂。